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Abstract 15 
Strategies to reduce antiretroviral doses and drug cost can support global access and 16 
numerous options are being investigated. Efavirenz pharmacokinetic simulation generated 17 
with a bottom-up physiologically based model were successfully compared with data 18 
obtained from the Encore I clinical trial (Efavirenz 400mg qd versus 600mg qd). These 19 
findings represent a pivotal paradigm for the prediction of pharmacokinetics resulting from 20 
dose reductions. Validated computational models constitute a valuable resource to optimise 21 
therapeutic options and predict complex clinical scenarios. 22 
Main text 23 
The global access to treatment will favour a more effective strategy against the HIV 24 
pandemic but defines several challenges in terms of drug production and distribution. 25 
Antiretroviral dosing strategies have been selected to warrant inhibition of viral replication 26 
but there is growing recognition that some antiretroviral drugs may be administered at doses 27 
above those required for efficacy.  This may place a higher demand than necessary on 28 
medication budgets and manufacturing costs in resource-limited settings where the need is 29 
greatest.  30 
Alternative strategies to lower doses and drug cost could effectively support global access 31 
and several reduction strategies are being investigated (1). A rational identification of optimal 32 
dose reductions is challenging and is commonly based on large clinical studies. 33 
Drug distribution can be quantitatively investigated through computational approaches, 34 
utilising data from clinical studies to provide a Top-down description and its variability in 35 
populations (i.e population pharmacokinetic modelling, popPK) or integrating drug specific in 36 
vitro data in models to predict Bottom-up pharmacokinetics in populations of virtual patients 37 
(i.e physiologically based pharmacokinetic modelling, PBPK). PBPK modelling is based on 38 
the mathematical representation of absorption, distribution and elimination processes 39 
defining pharmacokinetics (2). Drug specific (lypophilicity, apparent permeability, in vitro 40 
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clearance, induction and inhibition potential) and patient specific factors (demographics, 41 
enzyme expression, organ volume and blood flows) are integrated in order to provide a 42 
realistic description of pharmacokinetics (3-5). A virtual population of patients can be 43 
simulated by considering anatomical and physiological characteristics, and their covariance.  44 
The pharmacokinetic assessment after administration of efavirenz (EFV) 400mg once daily 45 
(qd) versus 600mg qd conducted as part of the Encore I study was recently published (6). 46 
Prior to this clinical analysis we made a prediction of the drug exposure from 400mg using 47 
PBPK modelling that we also published 3 years previously (7).  48 
The purpose of this work is to exemplify the utility of PBPK modelling in exploration of the 49 
pharmacokinetic consequences of dose reduction by reporting a formal comparison of the 50 
previous PBPK prediction against the popPK model (top down) that was constructed with the 51 
clinical data from Encore I (6).  52 
The frequency of the CYP2B6 516 G>T genotype from our previously published PBPK 53 
model were amended to match the population of the Encore I trial to provide a more realistic 54 
description of the inter-patient variability. The median of pharmacokinetic variables such as 55 
Cmax , C12hr and C24hr obtained through the PBPK simulations and their variability were 56 
compared with model predicted PK parameters from Encore I. As shown in Figure 1 the key 57 
pharmacokinetic descriptors of EFV were accurately predicted by the PBPK model after 58 
correcting the frequency of CYP2B6 516G>T. The predicted pharmacokinetic variables (Cmax 59 
, C12hr and C24hr) were in satisfactory agreement with the data observed for the dose 60 
reduction to 400 mg. These findings can be viewed as a paradigm for prediction of the 61 
pharmacokinetic consequences of dose reduction. While PBPK modelling cannot help 62 
establish the accuracy of existing pharmacokinetic therapeutic cut-off values (which Encore I 63 
has shown is likely to be inaccurate for EFV), it can certainly help define the potential for 64 
pharmacokinetic success prior to costly and labour-intensive prospective clinical trials. 65 
Therefore, integration of PBPK modelling prior to or during design of prospective studies is 66 
warranted to ensure effective deployment of available resources.  67 
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It is increasingly evident that computational approaches can assist in answering questions 68 
that cannot easily be examined because of prohibitive ethical or logistical barriers. PBPK 69 
modelling can bridge from drug development through in vitro data into the clinical scenario 70 
and reduce the number of clinical studies required to optimise therapies. This modelling 71 
approach can support the design of clinical studies in terms of sample size, timing of doses 72 
and sampling as recently indicated in several regulatory guidelines and documents (8-10). 73 
Our findings demonstrate the utility of PBPK modelling for dose optimisation, and a 74 
comparison between Bottom-Up and Top-Down approaches can build the basis for a future 75 
wider application of this modelling approach (11-13). The pharmacology of antiretrovirals 76 
and other anti-infective drugs is based on the co-administration of complex regimens and 77 
often administered to patients with specific characteristics defining challenging clinical 78 
scenarios (14, 15). Computational predictive models such as PBPK can represent a pivotal 79 
resource in answering questions that cannot otherwise be examined in pre-clinical or clinical 80 
development, supporting the rational design of therapeutic options, identifying strategies to 81 
maximise the efficiency and safety of therapies in various populations of patients.  82 
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Figure 1 Scatter dot representing the main pharmacokinetic descriptors (AUC0-24, Cmax, and 85 
C24hr) simulated through the PBPK model (7)and population PK model developed for 86 
ENCORE I (6) for 400mg qd (A) or 600 mg (B). 25th percentile (open circle), median (black 87 
circle) and 75th percentile (patterned circle) are presented. The solid line represents the 88 
identity line and dotted lines represent 50-200% range 89 
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